ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Ernexa Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.98−0.11 (-5.26%)
Close on Oct 19, 2026
- Market cap
- $2.34M
- P/E (TTM)
- –
- Dividend yield
- –
Ernexa Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Ernexa Therapeutics | Industry median |
|---|---|---|
| Market Cap | $3.23M | $197.05M |
| Enterprise Value | -$1.80M | $106.56M |
| PB Ratio | 1.01 | 2.14 |
| P/TBV Ratio | 1.01 | 2.46 |
Income (trailing twelve months)
| Measure | Ernexa Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$13.78M | -$21.44M |
| Pretax Income | -$12.35M | -$14.45M |
| Net Income | -$12.26M | -$22.46M |
| EBITDA | -$13.56M | -$16.91M |
Returns
| Measure | Ernexa Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -320.7% | -53.1% |
| Return on Assets (ROA) | -176.4% | -41.0% |
| Return on Capital Employed (ROCE) | -407.4% | -37.8% |
Balance sheet
| Measure | Ernexa Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.03M | $62.42M |
| Net Cash (Debt) | $5.03M | $15.68M |
| Net Cash Per Share | $3.08 | $0.65 |
| Equity (Book Value) | $3.20M | $48.79M |
| Book Value Per Share | $1.96 | $1.36 |
| Tangible Book Value | $3.20M | $23.06M |
| Working Capital | $2.96M | $75.77M |
Financial position
| Measure | Ernexa Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 2.01 | 3.30 |
| Quick Ratio | 1.71 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Ernexa Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$8.84M | -$12.35M |
Efficiency
| Measure | Ernexa Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.45M | -$732.08K |
| Employee Count | 5 | 73 |
Dividends and yields
| Measure | Ernexa Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -379.2% | -21.2% |
Shares
| Measure | Ernexa Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 1,632,410 | 59,128,900 |
| Shares Change (QoQ) | 0.34% | 0.54% |
Taxes
| Measure | Ernexa Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$96.00K | $91.50K |
Scores
| Measure | Ernexa Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -62.58 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Ernexa Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.